Abstract
Anticoagulation therapy reduces the risk for systemic embolism in patients with atrial fibrillation (AF). To test the value of adding an antiplatelet agent, researchers in Spain conducted a multicenter randomized trial involving 1209 patients with paroxysmal AF stratified according to their risk for systemic embolism: high (495 patients; mean age, 67) or intermediate (714 patients; mean age, 70). Among the high-risk patients were those with prior embolism …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
